Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have been given an average rating of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $20.00.

ABEO has been the topic of several research analyst reports. Weiss Ratings cut shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, October 13th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

Abeona Therapeutics Trading Down 1.5%

Shares of Abeona Therapeutics stock opened at $5.37 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The business has a fifty day simple moving average of $4.93 and a two-hundred day simple moving average of $5.72. Abeona Therapeutics has a 1 year low of $3.93 and a 1 year high of $7.54. The company has a market capitalization of $291.00 million, a price-to-earnings ratio of 4.37 and a beta of 1.12.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. Research analysts forecast that Abeona Therapeutics will post -1.16 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Vishwas Seshadri sold 25,000 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $5.31, for a total value of $132,750.00. Following the completion of the sale, the chief executive officer owned 1,164,818 shares of the company’s stock, valued at approximately $6,185,183.58. The trade was a 2.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark Alvino sold 15,000 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $4.74, for a total transaction of $71,100.00. Following the completion of the transaction, the director owned 62,252 shares in the company, valued at $295,074.48. This trade represents a 19.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 40,249 shares of company stock worth $205,217. Insiders own 5.40% of the company’s stock.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. bought a new position in shares of Abeona Therapeutics during the second quarter worth approximately $25,000. Legal & General Group Plc bought a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Abeona Therapeutics during the third quarter worth approximately $37,000. Legato Capital Management LLC bought a new position in Abeona Therapeutics during the 3rd quarter worth $57,000. Finally, Riverwater Partners LLC bought a new position in Abeona Therapeutics during the 2nd quarter worth $62,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.